Fusion Polypeptide Comprising Immunoglobulin Hinge Region for Extended In Vivo Period
Summary
The USPTO issued US Patent 12,612,469 B2 to LG CHEM, LTD. on April 28, 2026, granting exclusive rights to a fusion polypeptide technology comprising a target polypeptide fused to an immunoglobulin hinge region, which may be used to extend the in vivo half-life of therapeutic proteins. The patent application was originally filed on September 4, 2019, and contains 10 claims covering the fusion polypeptide composition, pharmaceutical compositions containing it, and methods of increasing protein circulation time. This grant provides LG Chem with intellectual property protection that precludes competitors from practicing the specified fusion polypeptide technology in the United States.
“Disclosed are a fusion polypeptide comprising a target polypeptide and a hinge region of an immunoglobulin; a pharmaceutical composition containing the fusion polypeptide; and a method for increasing the in vivo period of a target polypeptide, comprising a step of fusing a hinge region of an immunoglobulin with the target polypeptide.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
The USPTO granted patent US12612469B2 to LG CHEM, LTD., covering a fusion polypeptide comprising a target polypeptide fused to a hinge region of an immunoglobulin. The patent also protects pharmaceutical compositions containing the fusion polypeptide and methods for increasing the in vivo period of a target polypeptide by fusing it with an immunoglobulin hinge region. The patent contains 10 claims and was granted on April 28, 2026, with an original filing date of September 4, 2019.
Affected parties include pharmaceutical and biotechnology companies developing protein-based therapeutics, particularly those working on half-life extension technologies for biologic drugs. Competitors pursuing similar immunoglobulin hinge-based fusion strategies should review this patent to assess potential freedom-to-operate implications or consider licensing discussions with LG CHEM.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Fusion polypeptide comprising polypeptide region that can be O-glycosylated
Grant US12612469B2 Kind: B2 Apr 28, 2026
Assignee
LG CHEM, LTD.
Inventors
Yeonchul Kim, Seung Joo Lee, Jong Uk Koh, Kyuyong Kim, Saem Jung, Young Dok Son
Abstract
Disclosed are a fusion polypeptide comprising a target polypeptide and a hinge region of an immunoglobulin; a pharmaceutical composition containing the fusion polypeptide; and a method for increasing the in vivo period of a target polypeptide, comprising a step of fusing a hinge region of an immunoglobulin with the target polypeptide.
CPC Classifications
C07K 2317/53 C07K 19/00 C07K 2319/31 C07K 2317/41 C07K 2317/94
Filing Date
2019-09-04
Application No.
17273591
Claims
10
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.